. Author manuscript; available in PMC: 2009 Feb 15.

Published in final edited form as: J Infect Dis. 2008 Feb 15;197(4):519–526. doi: 10.1086/526787

Table 4.

Adjusted differences in malaria-related clinical outcomes for Kenyan children with and those without high levels of IgG antibodies to circumsporozoite protein (CSP), liver-stage antigen type 1 (LSA-1), and thrombospondin-related adhesive protein (TRAP).

	Risk of clinical malaria		Cumulative incidence of malaria (multiple episodes)		Change in Hb level, g/dL
Antigens	HR (95% CI)	P^a	IRR (95% CI)	P^b	Mean difference (95% CI)	P^c
CSP, LSA-1, TRAP	0.29 (0.10–0.81)	.02	0.29 (0.11–0.74)	.009	+1.00 (+0.25 to +1.75)	.009

CSP, LSA-1	0.43 (0.21–0.88)	.02	0.58 (0.31–1.08)	.09	+1.07 (+0.45 to +1.68)	.001

NOTE. All values are adjusted for age, bed net use, and parasitemia at the time of enrollment. CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio.

By Cox regression analysis.

By negative binomial regression analysis.

By multiple linear regression analysis.